These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 25159073)

  • 1. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.
    Heckman PR; Wouters C; Prickaerts J
    Curr Pharm Des; 2015; 21(3):317-31. PubMed ID: 25159073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases.
    Heckman PRA; Blokland A; Prickaerts J
    Adv Neurobiol; 2017; 17():135-168. PubMed ID: 28956332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Prickaerts J; Heckman PRA; Blokland A
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1033-1048. PubMed ID: 28772081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
    Xi M; Sun T; Chai S; Xie M; Chen S; Deng L; Du K; Shen R; Sun H
    Eur J Med Chem; 2022 Mar; 232():114170. PubMed ID: 35144038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.
    Reneerkens OA; Rutten K; Steinbusch HW; Blokland A; Prickaerts J
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):419-43. PubMed ID: 18709359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase inhibitors say NO to Alzheimer's disease.
    Nabavi SM; Talarek S; Listos J; Nabavi SF; Devi KP; Roberto de Oliveira M; Tewari D; Argüelles S; Mehrzadi S; Hosseinzadeh A; D'onofrio G; Orhan IE; Sureda A; Xu S; Momtaz S; Farzaei MH
    Food Chem Toxicol; 2019 Dec; 134():110822. PubMed ID: 31536753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDE and cognitive processing: beyond the memory domain.
    Heckman PR; Blokland A; Ramaekers J; Prickaerts J
    Neurobiol Learn Mem; 2015 Mar; 119():108-22. PubMed ID: 25464010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease.
    Sharma VK; Singh TG; Singh S
    Curr Drug Targets; 2020; 21(13):1371-1384. PubMed ID: 32718286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
    Wu Y; Li Z; Huang YY; Wu D; Luo HB
    J Med Chem; 2018 Jul; 61(13):5467-5483. PubMed ID: 29363967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herbs to curb cyclic nucleotide phosphodiesterase and their potential role in Alzheimer's disease.
    Kumar A; Sharma V; Singh VP; Kaundal M; Gupta MK; Bariwal J; Deshmukh R
    Mech Ageing Dev; 2015 Jul; 149():75-87. PubMed ID: 26050556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J
    Neuropharmacology; 2013 Jan; 64():124-36. PubMed ID: 22771768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis.
    Kyoi T; Oka M; Noda K; Ukai Y
    Life Sci; 2004 Aug; 75(15):1833-42. PubMed ID: 15302227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of phosphodiesterase isozymes in osteoblastic differentiation.
    Wakabayashi S; Tsutsumimoto T; Kawasaki S; Kinoshita T; Horiuchi H; Takaoka K
    J Bone Miner Res; 2002 Feb; 17(2):249-56. PubMed ID: 11811555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase inhibition in cognitive decline.
    García-Barroso C; Ugarte A; Martínez M; Rico AJ; Lanciego JL; Franco R; Oyarzabal J; Cuadrado-Tejedor M; García-Osta A
    J Alzheimers Dis; 2014; 42 Suppl 4():S561-73. PubMed ID: 25125473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase (PDE) III inhibitor, Cilostazol, improved memory impairment in aluminum chloride-treated rats: modulation of cAMP/CREB pathway.
    Khalifa M; Abdelsalam RM; Safar MM; Zaki HF
    Inflammopharmacology; 2022 Dec; 30(6):2477-2488. PubMed ID: 35727381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
    Gulisano W; Tropea MR; Arancio O; Palmeri A; Puzzo D
    Neuropharmacology; 2018 Aug; 138():151-159. PubMed ID: 29885420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D.
    Sierksma AS; van den Hove DL; Pfau F; Philippens M; Bruno O; Fedele E; Ricciarelli R; Steinbusch HW; Vanmierlo T; Prickaerts J
    Neuropharmacology; 2014 Feb; 77():120-30. PubMed ID: 24067928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase Targets for Cognitive Dysfunction and Schizophrenia--a New York Academy of Sciences Meeting.
    Zhang HT
    IDrugs; 2010 Mar; 13(3):166-8. PubMed ID: 20191432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction.
    Duinen MV; Reneerkens OA; Lambrecht L; Sambeth A; Rutten BP; Os JV; Blokland A; Prickaerts J
    Curr Pharm Des; 2015; 21(26):3813-28. PubMed ID: 26044976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment.
    Yanai S; Endo S
    Mol Neurobiol; 2019 Jun; 56(6):4306-4316. PubMed ID: 30311144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.